Research programme: immune tyrosine kinase inhibitors - Pfizer

Drug Profile

Research programme: immune tyrosine kinase inhibitors - Pfizer

Latest Information Update: 14 Nov 2005

Price : $50

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Immunosuppression; Inflammation

Most Recent Events

  • 14 Nov 2005 No development reported - Preclinical for Inflammation in USA (unspecified route)
  • 14 Nov 2005 No development reported - Preclinical for Immunosuppression in USA (unspecified route)
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top